Ignite Creation Date:
2024-10-25 @ 7:58 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06604325
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-17
Brief Title:
Prophylactic Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Prophylactic Role Of Tranexamic Acid To Reduce Blood Loss During Caesarean Delivery A Prospective Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Postpartum hemorrhage continues to be the leading cause of maternal morbidity and mortality Globally it is responsible for 25 of all pregnancy-related deaths PPH is unpredictable and may occur in the absence of risk factors Tranexamic acid is an antifibrinolytic proven to reduce blood loss and transfusion requirements for various surgeries This study aims to explore the effectiveness of tranexamic acid as an adjunct to other uterotonics before the Caesarian Section
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None